Skip to main content
Roche's Chugai sues Alexion to block launch of Ultomiris

Roche's Chugai has filed a patent lawsuit against Alexion for allegedly infringing on the technology used in Alexion's Ultomiris, which is indicated for the treatment of atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria. At issue is technology that reduces Ultomiris' typical dosing to once every eight weeks from predecessor Soliris' biweekly dosing.

Full Story: